JHTV
@jhtechventures
JHTV brings the benefits of discovery to the world. Contact us! #Entrepreneurship #Innovation #StartUps
RTs & links are not endorsements or warranties.
ID: 89570058
http://ventures.jhu.edu 12-11-2009 23:28:16
7,7K Tweet
3,3K Takipçi
1,1K Takip Edilen
Great news for CEO Teresa Prego & jairo tavera's EpiWatch Johns Hopkins Epilepsy Center winning Baltimore Business Journal's INNO Fire Award! Created for the Apple Watch to detect epileptic seizures, the app already has a waiting list! bit.ly/3S30tSL
Great to see Brené Brown 's interview with Lauren Choi, Pava Marie LaPere Center for Entrepreneurship and Johns Hopkins Engineering alum and founder of The New Norm, a company reshaping the future of plastics! bit.ly/3zMthJ4
Using genetic engineering techniques, a team of investigators, including JHTV, from Sidney Kimmel Comprehensive Cancer Center and its Ludwig Center, the Lustgarten Laboratory & Bloomberg~Kimmel Institute , have designed a novel cell type to recognize and fight cancer. bit.ly/3y22198 #innovation
Unique among universities, Johns Hopkins University' research development team stands out by assisting faculty in securing large-scale grants through their tailored proposal development support & thoughtful fostering of collaboration across disciplines. bit.ly/4cO4HWV Denis Wirtz
New gene-editing approach offers hope to sickle cell patients! Xizhen Lian researcher with Johns Hopkins Engineering The Institute for NanoBioTechnology (INBT) Johns Hopkins Medicine, says "This gene editing approach would allow patients to receive the medicine through a transfusion." bit.ly/4c3FeHJ
Our Maryland-Virginia-Washington DC Biohealth Capital Region has been ranked third in the nation, following San Francisco and Boston, among the top 10 Biopharma Clusters!bit.ly/3AcCVoM Johns Hopkins Engineering Johns Hopkins University @KimmelCancer The Institute for NanoBioTechnology (INBT)
Groundbreaking new drug for the treatment of a lethal type of brain cancer, called low-grade glioma, was approved on August 6th by the U.S. FDA. Vorasidenib, discovered by Johns Hopkins Kimmel Cancer Center, is the first ever hope for the treatment of glioma. Servier Pharmaceuticals bit.ly/46C1ur6
Great to see one of Johns Hopkins APL's & JHTV companies Oculi listed as one of EE Times | Electronic Engineering Times 100 startups to watch! bit.ly/4fBZ3Jk
Join Anchor Ventures on Sept 12 for Resources to Build Your Life Sciences Company in the Baltimore Region! Discover new resources & initiatives including Connect Labs Baltimore. UM Ventures, College Park shorturl.at/NyWS1
ICYMI in our July newsletter, we interviewed Sashank Reddy JHTV's Medical Director & Assoc. Director of The Institute for NanoBioTechnology (INBT) He's also the founder & president of LifeSprout Watch Reddy's video here ventures.jhu.edu/news/innovator…
A phase II clinical trial led by Johns Hopkins Kimmel Cancer Center reveals that the anti-cancer drug olaparib may treat biochemically recurrent prostate cancer in men with BRCA2 mutations w/o hormone therapy Cathy Handy Marshall, MD MPH & Emmanuel Antonarakis led the study published in JAMA Oncology shorturl.at/inMI8
New Breakthrough in Breast Cancer Research! Johns Hopkins Kimmel Cancer Center researchers have identified a potential immune system target to stop the spread of breast cancer cells. Could this lead to new immunotherapies? Read more in Oncogene. tinyurl.com/bdh63sr5